Genocea Biosciences Closes $23 Million Series A Financing, Names Vaccine Veteran Staph Leavenworth Bakali CEO.New Financing Led by SR One, the Corporate Venture Arm of GlaxoSmithKline, to Commercialize Novel Vaccine Discovery Platform CAMBRIDGE, Mass. -- Genocea Biosciences, a vaccine discovery and development company, today announced that it has raised a $23 million Series A financing led by SR One, the corporate venture arm of GlaxoSmithKline [GSK GSK GlaxoSmithKline plc (pharmaceutical company) GSK Glycogen Synthase Kinase GSK Gruppentraining Sozialer Kompetenzen (Germany) GSK Greenland Shark (FAO fish species code) ]. New investors Auriga Partners, Cycad cycad (sī`kăd), any plant of the order Cycadales, tropical and subtropical palmlike evergreens. The cycads, ginkgoes, and conifers comprise the three major orders of gymnosperms, or cone-bearing plants (see cone and plant). Group, and Alexandria Real Estate Equities also participated in the financing and were joined by returning founding investors Lux Capital Management, Polaris Venture Partners and Morningside Ventures. "Novel prophylactic and therapeutic vaccines are one of the most important unmet needs in global health," said SR-One Ltd President Russell Greig. "Genocea has a one-of-a-kind technology, strong business model, and outstanding team for developing vaccines against many of the world's remaining disease targets. SR-One is proud to be part of such a great syndicate and opportunity." In conjunction with the Series A financing, Genocea also appointed Executive Director Staph staph n. Staphylococcus. staph adj. Leavenworth Bakali as its new Chief Executive Officer. Leavenworth Bakali replaces Genocea co-founder Robert Paull, co-founder and Managing General Partner of Lux Capital Management. Paull will remain on Genocea's Board of Directors. "I'm thrilled to become Genocea's CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. ," said Leavenworth Bakali. "As founding CEO, Robert Paull assembled some of the most accomplished people in the vaccine sector and built a solid foundation for the next phase of Genocea's growth. The grand vision and tireless efforts of our scientific founder Darren Higgins, the Genocea team, and founding investors have positioned Genocea to be a tremendous success." Leavenworth Bakali brings 20 years of outstanding industry experience and repeated success. Through various senior operating and leadership positions, he has played a critical role in some of the most successful and leading vaccine companies. Leavenworth Bakali was formerly the Chief Operating Officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. of both ID Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. , a Vancouver, Canada-based developer of influenza vaccines that was acquired by GlaxoSmithKline for $1.4 billion; and PowderJect Pharmaceuticals, an Oxford, UK-based vaccine developer acquired by GlaxoSmithKline for $930 million. Leavenworth Bakali was also previously the Director of Worldwide Sales and Marketing at Chiron Vaccines and the Director of SmithKline Beecham's Vaccine Business Unit in France. Leavenworth Bakali is currently a non-executive Director at Vienna, Austria-based Intercell AG [VSE See DOS/VSE. VSE - Virtual Storage Extended :ICLL ICLL Index to Canadian Legal Literature ]. He holds a Masters in Management from London Business School Around 800 degree students, from 70 countries, graduate from the school each year. Over 80 percent of students, and over 70 percent of faculty, come from outside the UK. A further 6,000 executives attend the school executive education programmes each year. . "With the experienced leadership and prior successes of Staph Leavenworth Bakali as well as the support of leading international, U.S. and corporate investors, Genocea is poised to become the next great vaccine company," said Robert Paull. About Genocea Biosciences: Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. The company's proprietary T cell-directed antigen discovery program represents a broad platform with the potential to generate significant novel vaccines for multiple pathogens with high unmet medical need. Genocea is currently developing vaccines for chlamydia trachomatis Chlamydia tra·cho·ma·tis n. A species of Chlamydia that causes trachoma, inclusion conjunctivitis, lymphogranuloma venereum, nonspecific urethritis, and proctitis in humans. (a sexually transmitted disease sexually transmitted disease (STD) or venereal disease, term for infections acquired mainly through sexual contact. Five diseases were traditionally known as venereal diseases: gonorrhea, syphilis, and the less common granuloma inguinale, with an estimated 90 million cases worldwide), streptococcus pneumoniae (pneumonia is the leading killer of children under the age of five worldwide) and other undisclosed targets. In 2008, Genocea was selected as "Best Vaccine Startup" at the World Vaccine Congress and was selected one of the 15 most exciting biotech startup companies by FierceBiotech. Genocea is backed by leading investors including Lux Capital Management, Polaris Venture Partners, Morningside Ventures, SR One, Auriga Partners, Cycad Group and Alexandria Real Estate Equities. Visit www.genocea.com for more information. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion